Importantly, in vivo studies demonstrated that treatment with KRB-456 of mice bearing PDXs from pancreatic cancer patients resulted in inhibition of the PDX's P-MEK but not P-ERK levels. Here, MAP2K7 is linked to familial pancreatic carcinoma.